Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor α/γ agonist ragaglitazar

Journal of Medicinal Chemistry

Volumn 46, Issue 8, 2003, Pages 1306-1317

  Ebdrup, Søren ^a   Pettersson, Ingrid ^a   Rasmussen, Hanne B ^a   Deussen, Heinz Josef ^a   Jensen, Anette Frost ^a   Mortensen, Steen B ^a   Fleckner, Jan ^a   Pridal, Lone ^a   Nygaard, Lars ^a   Sauerberg, Per ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ARGININE; GW 2433; LY 465608; NNC 614655; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENOXAZINE DERIVATIVE; PIOGLITAZONE; RAGAGLITAZAR; ROSIGLITAZONE; TESAGLITAZAR; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG CONFORMATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOSELECTIVITY; ENZYME KINETICS; IC 50; RECEPTOR AFFINITY; SEQUENCE ALIGNMENT; STEREOCHEMISTRY;

BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HYPOGLYCEMIC AGENTS; LIGANDS; MODELS, MOLECULAR; OXAZINES; PHENYLPROPIONATES; RADIOLIGAND ASSAY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STEREOISOMERISM; TRANSCRIPTION FACTORS;

EID: 0037431401     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm021027r     Document Type: Article

References (67)

1. Ginsberg, H.; Plutzky, J.; Sobel, E. Review of metabolic and cardiovascular effects of oral antidiabetic agents: beyong glucose-level lowering. J. Cardivasc. Risk 1999, 6 (5), 337-346.
2. Cobb, J.; Dukes, I. Recent Advances in the Development of Agents for Treatment of Type 2 Diabetes. Annu. Rep. Med. Chem. 1998, 33, 213-221.
3. Grover, S. A.; Coupal, L.; Zowall, H.; Dorais, M. Cost-Effectiveness of Treating Hyperlipidemia in the Presence of Diabetes. Circulation 2000, 102, 722-727.
4. Bailey, C. J. Potential new treatments for type 2 diabetes. TIPS 2000, 21, 259-265.
5. Willson, T. M.; Brown, P. J.; Sternbach, D. D.; Henke, B. R. The PPARs: From orphan receptors to drug discovery. J. Med. Chem. 2000, 43, 527-550.
6. Staels, B.; Dallongeville, J.; Auwerx, J.; Schoonjans, K.; Leitersdorf, E.; Fruchart, J. -C. Mecanism of Action of Fibrates on Lipid and Lipoprotein Metabolism. Circulation 1998, 98, 2088-2093.
7. Chaput, E.; Saladin, R.; Silvestre, M.; Edgar, A. D. Fenofibrate and Rosiglitazone Lower Triglycerides with Opposing Effects on Body Weight. Biochem. Biophys. Res. Commun. 2000, 271, 445-450.
8. Boyle, P. J.; King, A. B.; Olansky, L.; Marchetti, A.; Lau, H.; Magar, R.; Martin J. Effects of Pioglitazone and Rosiglitazone on Blood Lipid Levels and Glycemic Control in Patients with Type 2 Diabetes Melitus: A Retrospective Review of Randomly Selected Medical Records. Clin. Ther. 2002, 24 (3), 378-396.
9. Chilcott, J.; Tappendem, P.; Jones, M. L.; Wight, J. P. A Systematic Review of the Clinical Effectiveness of Pioglitazone in the Treatment of Type 2 Diabetes Mellitus. Clin. Ther. 2001, 23, 1792-1823.
10. Wulff, E. M.; Jeppesen, L.; Bury, P. S.; Mogensen, J. P.; Fleckner, J.; Andersen, A.-S. T.; Wassermann, K.; Sauerberg, P.; Characterisation of a Future Generation Insulin Sensitizers in Vitro and in Vivo. Diabetes 2001, 50 (Suppl. 2), A524.
11. Sauerberg, P.; Pettersson, I.; Jeppesen, L.; Bury, P. S.; Mogensen, J. P.; Wasserman, K.; Brand, C. L.; Sturis, J.; Wöldike, H. F.; Fleckner, J.; Andersen, A.-S. T.; Mortensen, S. B.; Svensson, L. A.; Rasmussen, H. B.; Lehman, S. V.; Polivka, Z.; Sindelar, K.; Panajotova, V.; Ynddal, L.; Wulff, E. M. J. Novel tricyclic-α-alkyloxyphenylpropionic acids: Dual PPARα/γ agonists with hypolidemic and antidiabetic activity. J. Med. Chem. 2002, 45, 789-804.
12. Lohray, B. B.; Lohray, V. B.; Bajii, A. C.; Kalchar, S.; Poondra, R. R.; Padakanti, S.; Chakrabarti, R.; Vikramadithyan, R. K.; Misra, P.; Juluri, S.; Namidi, N. V. S. R.; Rajagopalan, R. (-)3-[4-[2-(phenoxazine-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: A Dual PPAR Agonist with Potent Antihyperglucemic and Lipid Modulating Activity. J. Med. Chem. 2001, 44, 2675-2678.
13. Kjellstedt, A.; Oakes, N.; Svensson, L.; Carlson, A.-C.; Ljung, B. AZ 242, a Novel PPARα/γ Agonist, Has Potent and Efficient Insulin-Sensitizing and Antidyslipidemic Properties in ob/ob Mice and fa/fa Zucker Rats. Diabetes 2001, 50 (Suppl. 2), A121.
14. Cronet, P.; Petersen, J. F. W.; Folmer, R.; Blomberg, N.; Sjöblom, K.; Karlsson, U.; Lindstedt, E.-L.; Bamberg, K. Structure of the PPARα and -γ ligand binding domain in complex with AZ 242; Ligand selectivity and agonist activation in the PPAR family. Structure 2001, 9, 699-706.
15. Murakami, K.; Tobe, K.; Ide, T.; Mochizuki, T.; Ohashi, M.; Akanuma, Y.; Yazaki, Y.; Kadowaki, T. A Novel Insulin Sensitizer Acts as a Coligand for Peroxisome Proliferator-Activated Receptor-α (PPAR-α) and PPAR-γ. Effects of PPAR-α Activation on Abnormal Lipid Metabolism in Liver of Zucker Fatty Rats. Diabetes 1998, 47, 1841-1847.
16. Etgen, G. J.; Oldham, B. A.; Johnson, W. T.; Broderick, C. L.; Montrose, C. R.; Brozinick, J. T.; Misener, E. A.; Bean, J. S.; Bensch, W. R.; Brooks, D. A.; Shuker, A. J.; Rito, C. J.; McCarthy, J. R.; Ardecky, R. J.; Tyhonas, J. S.; Dana, S. L.; Bilakovics, J. M.; Paterniti, J. R., Jr.; Ogilvie, K. M.; Liu, S.; Kauffman, R. F. A Tailored Therapy for the Metabolic Syndrome, The Dual Peroxisome Proliferator-Activated Receptor-α/γ Agonist LY465608 Ameliorates Insulin Resistance and Diabetic Hyperglycemia While Improving Cardiovascular Risk Factors in Preclinical Models. Diabetes 2002, 51, 1083-1087.
17. Saad, M. F.; Osel, K.; Lewin, A. J.; Patel, N.; Edwards, C. R.; Greco, S. Nunez, M.; Huang, W.-C.; Reinhardt, R. R. Ragaglitazar Improves Lipid Profile and Glycemic Control in Hypertriglyceridemic Type 2 Diabetes. Diabetes 2002, 51 (Suppl. 2), A35-A36.
18. Strand, J.; Sandeman, D.; Skovsted, B.; Edsberg, B.; Müller, P. Ragaglitazar (NNC 61-0029, (-)DRF 2725): The Efficacy and Safety of a Novel Dual PPARα and PPARγ Agonist in Patients with Type 2 Diabetes. Diabetes 2002, 51 (Suppl. 2), A141-A142.
19. Ebdrup, S.; Deussen, H.-J.; Zundel, M. Process for the preparation of substituted 3-phenyl-propanoic acid esters and substituted 3-phenyl-propanoic acids. PCT Appl. WO 0111072, 2001.
20. Deussen, H. J.; Zundel, M.; Valdois, M.; Lehmann, S. V.; Weil, V.; Hjort, C. M.; Ostergaard, P. R.; Marcussen, E.; Ebdrup, S. Process development on the enantioselective enzymatic hydrolyses of the (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)propanoate. Org. Proc. Res. Dev. 2003, 7, 82-88.
21. Grell, W.; Machleidt, H. PO-Aktivierte Alkoxyolifinierung. Justus Liebigs Ann. Chem. 1966, 53-67.
22. Wadsworth, W. S., Jr. Synthetic Applications of Phosphoryl-Stabilized Anions. Org. React. 1977, 25, 73-253.
23. Linde, H. Untersuchungen an Phenoxazinderivaten. Arch. Pharm. Ber. Dtsch. Pharm. Ges. 1960, 293, 537-542.
24. e mémoire) Reaction de metallation (Research in the phenothiazine series (part 3). Metalation reaction). Bull. Soc. Chim. Fr. 1960, 1049-1066.
25. Kim, S. H.; Martin, A. R. Tetracyclic Phenothiazines IV (1). Synthesis of 1,2,3,4-Tetrahydroazepino[3,2,1-kl]phenothiazine-4-one. J. Heterocycl. Chem. 1978, 15, 1503-1504.
26. Nygaard, L.; Wiede, P.; Jensen, A. F.; Olsen, H.; Ebdrup, S. Unpublished results.
27. SHELXTL. Software package for single crystal structure determination, version 5.1; Bruker AXS, Inc.: Madison, WI, 1997.
28. Crystallographic data for the structure has been deposited with the Cambridge Crystallographic Data Centre as Supplementary Publication No. CCDC 197689. Copies of the data can be obtained free of charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, U.K. or on e-mail, deposit@ccdc.ac.uk.
29. Nicols, J. S.; Parks, D. J.; Consler, T. G.; Blanchard, S. G. Development of a Scintilation Proximity Assay for Peroxisome Proliferator-Activation. Anal. Biochem. 1998, 112-119.
30. Skrumsager, B. K.; Nielsen, K. K.; Pedersen, P. C. NNC 61-0029 ((-)DRF2725): The multiple dose pharmacokinetics of a novel dual acting PPARalpha and PPARgamma agonist in healthy subjects and type 2 diabetic patients. Diabetes. 2001, 50 (Suppl. 2), A123-A132.
31. Skrumsager, B. K.; Nielsen, K. K.; Reinhardt, R.; Pedersen, P. C. NNC 61-0029 ((-)DRF2725): The single dose pharmacokinetics of a novel dual acting PPARalpha and PPARgamma agonist in caucasian and Japanese healthy subjects. Diabetes. 2001, 50 (Suppl. 2), A445.
32. Nolte, R. T.; Wisely, G. B.; Westin, S.; Cobb, J. E.; Lambert, M. H.; Kurokawa, R.; Rosenfeld, M. G.; Willson, T. M.; Glass, C. K.; Milburn, M. V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 1998, 395, 137-143.
33. Uppenberg, J.; Svensson, C.; Jaki, M.; Bertilsson, G.; Jendeberg, L.; Berkenstam, A. Crystal Structure of the Ligand Binding Domain of the Human Nuclear Receptor PPARγ. J. Biol. Chem. 1998, 273, 31108-31112.
34. Oberfield, J. L.; Collins, J. L.; Holmes, C. P.; Goreham, D. M.; Cooper, J. P.; Cobb, J. E.; Lenhard, J. M.; Hull-Ryde, E. A.; Mohr, C. P.; Blanchard, S. G.; Parks, D. J.; Moore, L. B.; Lehmann, J. M.; Plunket, K.; Miller, A. B.; Milburn, M. V.; Kliewer, S. A.; Willson, T. M. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 6102-6106.
35. Xu, H. E.; Lambert, M. H.; Montana, V. G.; Parks, D. J.; Blanchard, S. G.; Brown, P. J.; Sternbach, D. D.; Lehman, J. M.; Wisely, G. B.; Willson, T. M.; Kliewer, S. A.; Milburn, M. V. Molecular Recognition of Fatty Acids by Peroxisome Proliferator-Activated Receptors. Mol. Cell 1999, 3, 397-403.
36. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules J. Med. Chem. 1985, 28, 849-857.
37. Boobbyer, D. N. A.; Goodford, P. J.; McWhinnie, P. M.; Wade, R. C. New hydrogen-bond potentials for use in determining energetically favorable binding sites on molecules of known structure. J. Med. Chem. 1989, 32, 1083-1094.
38. Wade, R. C.; Goodford, P. J. Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. 2. Ligand probe groups with the ability to form more than two hydrogen bonds. J. Med. Chem. 1993, 36, 148-156.
39. Molecular Discovery Ltd., 20a Berkeley Street, Mayfair, London W1X 5AE, U.K.
40. Oliver, W. R.; Shenk, J. L.; Snaith, M. R.; Russel, C. S.; Plunket, K. D.; Bodkin, N. L.; Lewis, M. C.; Winegar, D. A.; Sznaidman, M. L.; Lambert, M. H.; Xu, H. E.; Sternbach, D. D.; Kliewer, S. A.; Hansen, B. C.; Willson, T. M. A selective peroxisome proliferator-activated receptor γ agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 5306-5311.
41. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A Fast Docking Method Using an Incremental Construction Algorithm. J. Mol. Biol. 1996, 261, 470-489.
42. Kramer, B.; Rarey, M.; Lengauer, L. Evaluation of the FlexX incremental construction algorithm for protein-ligand docking. Proteins: Struct., Funct., Genet. 1999, 37, 228-241.
43. Rarey, M.; Wefing, S.; Lengauer, T. Placement of medium-sized molecular fragments into active sites of proteins. J. Comput.-Aided Mol. Des. 1996, 10, 41-54.
44. Rarey, M.; Kramer, B.; Lengauer, T. Multiple automatic base selection: Protein-ligand docking based on incremental construction without manual intervention. J. Comput.-Aided Mol. Des. 1997, 11, 369-384.
45. Clark, R. D.; Strizhev, A.; Leonard, J. M.; Blake, J. F.; Matthew, J. B. Concensus scoring for ligand/protein interactions. J. Mol. Graphics Modell. 2002, 20, 281-295.
46. The enantiomeric purity can be significantly increased by diastereomer crystallization with (-)-ephedrine.
47. Cerenius, Y.; Stahl, K.; Svensson, L. A.; Ursby, T.; Oskarsson, A.; Albertsson, J.; Liljas, A. The crystallography beamline I711 at MAX II. J. Synchrotron Radiat. 2000, 7, 203-208.
48. Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. Methods Enzymol. 1997, 276, 307-326.
49. Collaborative Computational Project, N4. The CCP4 Suite: Programs for Protein Crystallography. Acta Crystallogr. 1994, D50, 760-763.
50. Navaza, J. Amore - an automated package for molecular replacement. Acta Crystallogr. 1994, A50, 157-163.
51. Brünger, A. T.; Kuriyan, J.; Karplus, M. Crystallographic R-factor refinement by molecular dynamics. Science 1987, 235, 458-460.
52. Brunger, A. T.; Adams, P. D.; Clore, G. M.; Delano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J.-S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, G. L.; Warren, T.; Badger, J.; Berard, D.; Kumar, R. A.; Szalma, S.; Yip, P.; Griesinger, C.; Junker, J. Crystallography and NMR System: A New Software Suite for Macromolecular Structure Determination. Acta Crystallogr. 1998, D54, 905-921.
53. Kleywegt, G. J.; Jones, T. A. Databases in Protein Crystallography. Acta Crystallogr. 1998, D54, 1119-1131.
54. SYBYL, version 6.8; Tripos Inc., 1699 South Hanley Road, St. Louis, Missouri, 63144.
55. Schrodinger Inc. (www.schrodinger.com).
56. Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. MacroModel - An Integrated Software System for Modeling Organic and Bioorganic Molecules Using Molecular Mechanics. J. Comput. Chem. 1990, 11, 440-467.
57. Goodman, J. M.; Still, W. C. An Unbounded Systematic Search of Conformational Space. J. Comput. Chem. 1991, 12, 1110-1117.
58. Halgren, T. A. Merck Molecular Force Field. I. Basis, Form, Scope, Parametrization, and Performance of MMFF94. J. Comput. Chem. 1996, 17, 490-519.
59. Halgren, T. A. Merck Molecular Force Field. II. MMFF94 van der Waals and Electrostatic Parameters for Intermolecular Interactions. J. Comput. Chem. 1996, 17, 520-552.
60. Halgren, T. A. Merck Molecular Force Field. III. Molecular Geometries and Vibrational Frequencies for MMFF94. J. Comput. Chem. 1996, 17, 553-586.
61. Halgren, T. A.; Nachbar, R. B. Merck Molecular Force Field. IV. Conformational Energies and Geometries for MMFF94. J. Comput. Chem. 1996, 17, 587-615.
62. Halgren, T. A. Merck Molecular Force Field. V. Extension of MMFF94 Using Experimental Data, Additional Computational Data, and Empirical Rules. J. Comput. Chem. 1996, 17, 616-641.
63. Halgren, T. A. MMFF VI. MMFF94s Option for Energy Minimization Studies. J. Comput. Chem. 1999, 20, 720-729.
64. Halgren, T. A. MMFF VII. Characterization of MMFF94, MMFF94s, and Other Widely Available Force Fields for Conformational Energies and for Intermolecular-Interaction Energies and Geometries. J. Comput. Chem. 1999, 20, 730-748.
65. Still, W. C.; Tempczyk, A.; Hawley, R. C.; Hendrickson, T. Semianalytical Treatment of Solvation for Molecular Mechanics and Dynamics. J. Am. Chem. Soc. 1990, 112, 6127-6129.
66. Kristensen, J. B.; Johansen, S. K.; Valsborg, J. S.; Martiny, L.; Foged, C. Unpublished results.
67. Johansen, S. K.; Martiny, L. Unpublished results.